Skip to content
Open in App
BridgeBio Pharma logo

BridgeBio Pharma

web2

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicine...

Symbol · 1BBIO
Company profile

About

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

FP

Frank P. McCormick

Co-Founder, Chairman of Oncology & Director

Company leadership profile.

DA

Douglas Adam Dachille

Independent Director

Company leadership profile.

JC

James C. Momtazee

Independent Director

Company leadership profile.

JE

Jennifer E. Cook

Independent Director

Company leadership profile.

NK

Neil Kumar

Co-Founder, CEO & Director

Company leadership profile.

CJ

Charles J. Homcy

Co-Founder, Chairman of Pharmaceuticals & Lead Director

Company leadership profile.

AJ

Ali J. Satvat

Independent Director

Company leadership profile.

FH

Fred Hassan

Lead Independent Director

Company leadership profile.

AJ

Andrea John Ellis

Independent Director

Company leadership profile.

EM

Eric M. Aguiar

Independent Director

Company leadership profile.

RJ

Ronald J. Daniels

Independent Director

Company leadership profile.

WL

Wen-Chaun Lo

Independent Director

Company leadership profile.

HA

Hannah A. Valantine

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated BridgeBio Pharma.

Orbitrum research

Experts evaluating BridgeBio Pharma

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment